PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Henry Ford Health System
Study ID
NCT04886726
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • uhCG/EGF — DRUG
    PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant

Study Details

So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival

Key Dates

Start date
Dec 23, 2021
Status verified
Feb 2026
Primary completion
Nov 30, 2028
Completion
Nov 30, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: PTCY and uhCG/EGF
    PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant

Primary Outcome Measure

MTD [ Time Frame: day+30 post SCT ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry Ford HospitalDetroitMichigan48202
shatha farhan
[email protected]
313-713-3910

Find similar trials in Detroit, MI

By research site
Henry Ford Hospital· Detroit, MI

Related Studies